Comparative Pharmacology
Head-to-head clinical analysis: AVANDAMET versus PIOGLITAZONE HYDROCHLORIDE AND GLIMEPIRIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AVANDAMET versus PIOGLITAZONE HYDROCHLORIDE AND GLIMEPIRIDE.
AVANDAMET vs PIOGLITAZONE HYDROCHLORIDE AND GLIMEPIRIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AVANDAMET combines rosiglitazone, a thiazolidinedione that improves insulin sensitivity by activating peroxisome proliferator-activated receptor gamma (PPARγ), and metformin, a biguanide that decreases hepatic glucose production, reduces intestinal glucose absorption, and improves insulin sensitivity.
Pioglitazone is a thiazolidinedione that acts as an agonist at peroxisome proliferator-activated receptor gamma (PPARγ), increasing insulin sensitivity in peripheral tissues and reducing hepatic gluconeogenesis. Glimepiride is a sulfonylurea that stimulates insulin secretion from pancreatic beta cells by blocking ATP-sensitive potassium channels.
Oral, initial dose of rosiglitazone 4 mg/metformin 500 mg twice daily or rosiglitazone 2 mg/metformin 500 mg twice daily; maximum recommended dose rosiglitazone 8 mg/metformin 2000 mg per day.
Oral, 1 tablet containing pioglitazone 15-30 mg and glimepiride 1-4 mg once daily with the first main meal; maximum daily doses: pioglitazone 45 mg, glimepiride 8 mg.
None Documented
None Documented
Rosiglitazone: 3-4 hours (terminal); metformin: 6.2 hours (terminal). No accumulation with normal renal function.
Pioglitazone: 3–7 hours (parent), 16–24 hours (active metabolites); clinically, once-daily dosing due to metabolite activity. Glimepiride: 5–9 hours (terminal), with prolonged effect in renal impairment.
Renal (90-95% as unchanged drug for rosiglitazone; metformin is 90% renally eliminated unchanged). Biliary/fecal: minor (<5% for both).
Pioglitazone: 30% renal (as metabolites, <2% unchanged); 70% fecal/biliary. Glimepiride: 60% renal (metabolites), 40% fecal/biliary.
Category C
Category A/B
Thiazolidinedione and Biguanide Combination
Thiazolidinedione